National MS Society: Results Published From Phase 3 Clinical Trials of Ofatumumab in Relapsing MS
August 06, 2020
August 06, 2020
NEW YORK, Aug. 6 -- The National Multiple Sclerosis Society issued the following news:
In two Phase 3 trials that included 1,882 people with relapsing MS, ofatumumab (Novartis) injected under the skin monthly reduced relapses significantly more than daily oral Aubagio(R) (teriflunomide, Sanofi Genzyme). Top-line results were announced in August 2019, and details have now been published in the peer-reviewed New England Journal of Medicine. Novartis has applied for approval from the U . . .
In two Phase 3 trials that included 1,882 people with relapsing MS, ofatumumab (Novartis) injected under the skin monthly reduced relapses significantly more than daily oral Aubagio(R) (teriflunomide, Sanofi Genzyme). Top-line results were announced in August 2019, and details have now been published in the peer-reviewed New England Journal of Medicine. Novartis has applied for approval from the U . . .